ACI’s 2nd Annual Summit on GLP-1 Law & Policy

The GLP-1 market is set to hit over $30 billion by 2030.  Intellectual property litigation and FDA crackdowns have led to a boom in M&A and partnership activity.  Long-term patient effects have yet to be fully realized.  The future of GLP-1s is bright, but ownership, liability, and regulatory priorities still hang in the balance.  That’s the backdrop for the American Conference Institute’s (“ACI”) 2nd Annual Summit on GLP-1 Law & Policy, which returns on June 4, 2026, at 3 Times Square, New York, NY.

ACI’s distinguished faculty of in-house counsel, representing innovators, compounders, providers, and more, alongside outside counsel with a bird’s-eye view, will spend one jam-packed day discussing the full spectrum of legal and regulatory challenges and market concerns facing the GLP-1 drug industry.  The conference will address everything—state and federal regulatory activity and FDA; advertising challenges across the media landscape; intellectual property disputes beyond the patent; mass torts and pharmacovigilance; the peptide boom and new market innovations; and more!

Hyman, Phelps & McNamara, P.C.’s Karla L. Palmer, along with Peter Pitts, President and Co-Founder of the Center for Medicine in the Public Interest, will co-present at a session titled “Prognostication Station: Anticipating the Long Tail of the GLP-1 Market.”  The session will consider the GLP-1 market as it exists today, and ponder what to expect for GLP-1 legislation, regulation, and litigation over the next 6 months, one year, five years, and beyond.

FDA Law Blog is a conference media partner. As such, we can offer our readers a special 10% discount. The discount code is: D10-999-FDA26. You can access the conference brochure and sign up for the event here.  We look forward to seeing you at the conference.